Edition:
India

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

1.68USD
15 Nov 2019
Change (% chg)

$-0.06 (-3.45%)
Prev Close
$1.74
Open
$1.74
Day's High
$1.74
Day's Low
$1.67
Volume
194,201
Avg. Vol
205,527
52-wk High
$4.09
52-wk Low
$1.67

Latest Key Developments (Source: Significant Developments)

AcelRx Pharmaceuticals Reports Third Quarter Results
Thursday, 7 Nov 2019 

Nov 6 (Reuters) - AcelRx Pharmaceuticals Inc ::ACELRX PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.16.Q3 EARNINGS PER SHARE ESTIMATE $-0.22 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS BALANCE OF $80.4 MILLION AS OF SEPTEMBER 30, 2019.  Full Article

Acelrx Pharma Reports Q2 Loss Per Share Of $0.16
Tuesday, 6 Aug 2019 

Aug 5 (Reuters) - AcelRx Pharmaceuticals Inc ::ACELRX PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.16.Q2 EARNINGS PER SHARE ESTIMATE $-0.22 -- REFINITIV IBES DATA.$91.5 MILLION OF CASH AND SHORT-TERM INVESTMENTS AT JUNE 30, 2019.  Full Article

Acelrx Added To The Russell 2000® And 3000® Indexes
Monday, 1 Jul 2019 

July 1 (Reuters) - AcelRx Pharmaceuticals Inc ::ACELRX ADDED TO THE RUSSELL 2000® AND 3000® INDEXES.  Full Article

Acelrx Pharma Inc Says May Offer And Sell Shares Of Common Stock Of Up To $46.6 Mln
Thursday, 9 May 2019 

May 9 (Reuters) - AcelRx Pharmaceuticals Inc ::ACELRX PHARMACEUTICALS INC SAYS MAY OFFER AND SELL SHARES OF COMMON STOCK OF UP TO $46.6 MILLION - SEC FILING.  Full Article

AcelRX Pharmaceuticals Says Public Offering Of 12.7 Mln Common Shares Priced At $3.15 Per Share
Friday, 9 Nov 2018 

Nov 9 (Reuters) - AcelRx Pharmaceuticals Inc ::ACELRX PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 12.7 MILLION COMMON SHARES PRICED AT $3.15 PER SHARE.  Full Article

Acelrx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Friday, 9 Nov 2018 

Nov 9 (Reuters) - AcelRx Pharmaceuticals Inc ::ACELRX PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ACELRX PHARMACEUTICALS - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND COMMERCIAL LAUNCH OF DSUVIA.  Full Article

Acelrx Pharmaceuticals Q3 Loss Per Share $0.21
Saturday, 3 Nov 2018 

Nov 2 (Reuters) - AcelRx Pharmaceuticals Inc ::ACELRX PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.21.Q3 EARNINGS PER SHARE VIEW $-0.21 -- THOMSON REUTERS I/B/E/S.ACELRX PHARMACEUTICALS - SEPTEMBER 30, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS BALANCE OF $63.6 MILLION.  Full Article

FDA Says Very Tight Restrictions Being Placed On Distribution And Use Of Dsuvia
Friday, 2 Nov 2018 

Nov 2 (Reuters) - U.S. Food and Drug Administration::STATEMENT FROM FDA COMMISSIONER SCOTT GOTTLIEB, M.D., ON AGENCY’S APPROVAL OF DSUVIA AND THE FDA’S FUTURE CONSIDERATION OF NEW OPIOIDS.U.S. FDA - WILL CONTINUE TO MONITOR IMPLEMENTATION OF RISK EVALUATION AND MITIGATION STRATEGY ASSOCIATED WITH ACELRX PHARMACEUTICALS' DSUVIA.FDA - THERE ARE VERY TIGHT RESTRICTIONS BEING PLACED ON THE DISTRIBUTION AND USE OF DSUVIA..U.S. FDA - DISTRIBUTION SYSTEM WILL RESTRICT DSUVIA’S USE TO CERTIFIED MEDICALLY-SUPERVISED HEALTH CARE SETTINGS.FDA SAYS ALSO RE-EVALUATING HOW FDA CONSIDERS BOTH INDIVIDUAL & PUBLIC HEALTH IMPACTS OF NEW OPIOIDS AS THEY ARE REVIEWED FOR APPROVAL.FDA COMMISSIONER GOTTLIEB SAYS ASKED PROFESSIONAL STAFF AT THE FDA TO EVALUATE A NEW FRAMEWORK FOR OPIOID ANALGESIC APPROVALS.GOTTLIEB SAYS DSUVIA CAN’T BE DISPENSED TO PATIENTS FOR HOME USE AND SHOULD NOT BE USED FOR MORE THAN 72 HOURS.U.S. FDA - MILITARY APPLICATION FOR DSUVIA WAS CAREFULLY CONSIDERED.GOTTLIEB SAYS DSUVIA WON’T BE AVAILABLE AT RETAIL PHARMACIES FOR PATIENTS TO TAKE HOME.FDA SAYS LIKE ALL OPIOIDS, ACELRX PHARMACEUTICALS' DSUVIA WILL ALSO CARRY BOXED WARNING ABOUT SERIOUS RISKS OF MISUSE & ABUSE.  Full Article

Acelrx Announces FDA Approval Of Dsuvia
Friday, 2 Nov 2018 

Nov 2 (Reuters) - AcelRx Pharmaceuticals Inc ::ACELRX SAYS ANNOUNCES FDA APPROVAL OF DSUVIA, U.S. LAUNCH OF DSUVIA EXPECTED IN THE FIRST QUARTER OF 2019.ACELRX ON DSUVIA SAYS WILL DE-CERTIFY HEALTHCARE SETTINGS THAT ARE NON-COMPLIANT WITH REMS PROGRAM.  Full Article

Industry Ventures Secondary VIII Reports 7.30 Pct Passive Stake In Acelrx Pharmaceuticals
Thursday, 31 May 2018 

May 31 (Reuters) - AcelRx Pharmaceuticals Inc ::INDUSTRY VENTURES SECONDARY VIII, L.P. REPORTS 7.30 PERCENT PASSIVE STAKE IN ACELRX PHARMACEUTICALS INC AS OF MAY 21, 2018 - SEC FILING.  Full Article